Hereditary Angioedema - Takhzyro
Customize your policy alerts
Sign up for Cigna Policy IP0334 alerts
Get alerted when Policy IP0334 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and benefit coverage for Takhzyro (lanadelumab-flyo) used to prevent attacks of hereditary angioedema due to C1-inhibitor deficiency. It applies to health benefit plans administered by Cigna, subject to the applicable benefit plan, laws, and individual clinical circumstances.
Coverage now requires hereditary angioedema type I or type II due to C1-inhibitor deficiency, with low functional C1-inhibitor and low serum C4 levels at baseline.
The prior requirement for low baseline C1-inhibitor antigenic levels was removed.
Continuation therapy criteria were added for patients currently receiving Takhzyro prophylaxis.
The specialist requirement was expanded to include a physician who specializes in treating HAE or related disorders.
The prior explicit criterion prohibiting concomitant use with other FDA-approved HAE prophylactic treatments was removed from the approval criteria.
The policy title and criteria changes documented for earlier revisions remain part of the revision history.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.